ALNY PEER ANALYSIS

Alnylam Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

ALNYAlnylam Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ALNYIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ALNY	CSL	TLX	MSB	Ind. Median
P/E	74.90	29.44●	—	—	17.91
P/B	40.20	2.20●	6.37	—	3.51
EV/EBITDA	44.89	10.21●	120.14	—	14.82
P/S	10.09	2.62●	3.24	31.61	10.89

Financial Health
Metric	ALNY	CSL	TLX	MSB	Ind. Median
Current Ratio	3.13●	2.57	1.43	—	5.90
Debt/Equity	118.4%	67.4%●	112.3%	—	10.9%
NetDebt/EBITDA	-1.88●	2.22	13.13	—	1.15

Profitability
Metric	ALNY	CSL	TLX	MSB	Ind. Median
Net Margin	13.5%●	9.2%	-0.9%	-115.3%	-125.7%
ROE	96.9%●	7.7%	-1.8%	-11.3%	-47.5%
ROA	12.4%●	3.8%	-0.7%	-8.6%	-35.8%
EBITDA Margin	21.6%	32.8%●	3.0%	-76.6%	-105.8%

Growth + Dividend
Metric	ALNY	CSL	TLX	MSB	Ind. Median
Rev. Growth	82.6%	4.8%	56.3%	410.4%●	5.1%
NI Growth	—	-39.4%	—	—	12.1%
Div. Yield	—	2.5%●	—	0.0%	0.2%
Payout	—	103.1%	—	0.0%	0.0%

Valuation
Metric	ALNY	RVMD	RPRX	MRNA	ROIV	REGN	Ind. Median
P/E	74.90	—	39.06	—	—	15.93●	17.91
P/B	40.20	24.99	4.69	4.25	6.30	2.24●	3.51
EV/EBITDA	44.89	—	23.94	—	—	11.21●	14.82
P/S	10.09	—	13.25	14.16	3,454.68	4.72●	10.89

Financial Health
Metric	ALNY	RVMD	RPRX	MRNA	ROIV	REGN	Ind. Median
Current Ratio	3.13	6.80	2.66	2.41	18.37●	3.57	5.90
Debt/Equity	118.4%	29.2%	130.0%	17.5%	2.4%●	8.6%	10.9%
NetDebt/EBITDA	-1.88●	1.12	4.91	1.35	16.03	-1.05	1.15

Profitability
Metric	ALNY	RVMD	RPRX	MRNA	ROIV	REGN	Ind. Median
Net Margin	13.5%	—	33.9%●	-143.6%	-3,629.2%	29.6%	-125.7%
ROE	96.9%●	-76.7%	12.2%	-36.6%	-6.5%	14.5%	-47.5%
ROA	12.4%●	-59.4%	4.4%	-26.4%	-5.4%	11.3%	-35.8%
EBITDA Margin	21.6%	—	69.6%●	-129.7%	-3,162.6%	38.5%	-105.8%

Growth + Dividend
Metric	ALNY	RVMD	RPRX	MRNA	ROIV	REGN	Ind. Median
Rev. Growth	82.6%●	-100.0%	7.8%	-29.1%	-67.7%	5.9%	5.1%
NI Growth	—	—	-24.3%	—	—	-1.7%●	12.1%
Div. Yield	—	—	1.6%●	—	—	0.6%	0.2%
Payout	—	—	46.8%	—	—	8.5%	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ALNY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.